Related Experiment Videos
The level at which blood pressure should be treated
1Department of Medicine, University of Leicester, UK.
Insights
Treating mild to moderate hypertension significantly reduces stroke risk. However, the benefits for ischemic heart disease are less clear, and treatment thresholds remain arbitrary, with newer drug costs a consideration.
Area of Science:
- Cardiology
- Hypertension Management
- Clinical Trials
Background:
- Large trials confirm hypertension treatment reduces stroke risk.
- Impact of treatment on ischemic heart disease remains debated.
- Blood pressure risk is continuous, making treatment thresholds arbitrary.
Purpose of the Study:
- To evaluate the established benefits of hypertension treatment.
- To discuss the arbitrary nature of current treatment guidelines.
- To consider the role and cost-effectiveness of newer antihypertensive agents.
Main Methods:
- Analysis of large multicenter trials on mild to moderate hypertension.
- Review of subgroup analyses from MRC and Australian Therapeutic Trials.
- Assessment of evidence for newer drug classes like ACE inhibitors and calcium-channel blockers.
Main Results:
- Treatment unequivocally reverses stroke risk in mild to moderate hypertension.
- Benefits for ischemic heart disease are less certain.
- Current guidelines (e.g., British Hypertension Society) recommend treating diastolic pressure ≥100 mmHg based on empirical data.
Conclusions:
- Hypertension treatment is vital for stroke prevention.
- The optimal blood pressure target for treatment is not definitively established.
- Further end-point trials are needed to assess newer agents and their cost-effectiveness before widespread first-line use.
Abstract:
The large multicenter trials of treatment in mild to moderate hypertension have shown unequivocally that the risk of stroke is reversed. The impact of treatment on ischemic heart disease is more debatable. Since there is no discontinuity in the risk of different levels of blood pressure, any advice about the level of pressure to treat must be arbitrary. The British Hypertension Society Guidelines recommend a sustained diastolic pressure of 100 mmHg or more over a 3- to 4-month period. This empirical advice is based upon subgroup analysis of the MRC and Australian Therapeutic Trials that suggests most of the benefit in treating the mildest degrees of hypertension occur in this group of patients. The role of newer classes of agent, such as ACE inhibitors or calcium-channel blockers, cannot be fully assessed in the absence of proper end-point trials. Whilst reasons for using these agents as first-line therapy have been put forward, these remain speculative in the absence of such trials. The much greater cost of newer agents in the context of universally cost-constrained health services also has to be borne in mind before recommending their widespread use as first-line therapy.